{
  "outcomes_metadata": {
    "timestamp": "2025-10-01T15:38:01.035232",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 109,
    "source_countries": [
      "AT",
      "BE",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "all-cause mortality (death due to any cause)",
        "mortality",
        "treatment-related mortality",
        "annual mortality",
        "perioperative mortality",
        "recurrence-free survival",
        "disease-free survival",
        "disease-free survivorship",
        "improved survival",
        "survival",
        "progression-free survival (PFS)",
        "progression-free survival (RECIST 1.1)",
        "progression-free survival (modified RECIST criteria)",
        "progression-free survivorship",
        "time to symptomatic progression (TTSP)",
        "time to symptomatic disease progression (FHSI-8 questionnaire)",
        "time to radiological disease progression",
        "time to radiologic progression",
        "time to deterioration",
        "time to treatment discontinuation",
        "duration of treatment",
        "time on treatment (TTD)",
        "progression-free state",
        "progressive illness state",
        "death"
      ],
      "response_measures": [
        "overall response rate (ORR)",
        "objective response rate (ORR; RECIST 1.1)",
        "objective response rate (ORR; mRECIST)",
        "objective response (mRECIST)",
        "objective response (RECIST 1.1)",
        "objective tumour response",
        "tumor response rate",
        "tumour response",
        "tumour response (mRECIST test)",
        "tumour response (RECIST criteria)",
        "tumour response (LR-TR criteria: viable, equivocal, nonviable)",
        "response rates (RECIST criteria)",
        "response rates",
        "partial response (PR)",
        "partial response (radiological, independently assessed)",
        "minor response (reduction of tumour size by 25 to 50%)",
        "complete response (CR)",
        "complete response",
        "stable disease (SD)",
        "stable disease (for at least 16 weeks)",
        "disease control rate (DCR)",
        "disease control rate (DCR; mRECIST)",
        "disease control",
        "clinical benefit rate (CBR)",
        "tumor reduction",
        "local control",
        "local tumour control",
        "local tumor control",
        "local recurrence",
        "recurrence",
        "recurrence rate",
        "bridge to transplant",
        "down-staging"
      ],
      "progression_measures": [
        "time to progression (TTP)",
        "time to progression",
        "time-to-progression",
        "time to progression of the tumor",
        "time to tumour progression",
        "disease progression",
        "tumor progression",
        "progression-free survival (PFS; RECIST 1.1)",
        "time-to-symptom worsening (TSW; EORTC QLQ-C30)",
        "time-to-symptom worsening (TSW; EORTC QLQ-HCC18)",
        "time-to-symptom worsening (TSW; EQ-5D VAS)",
        "time-to-symptom worsening (TSW; EQ-5D HUI)"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (general)",
        "adverse events (graded according to the National Cancer Institute)",
        "adverse events (grade 3-4)",
        "adverse events (grade 5)",
        "adverse events (grade 3 and higher or serious/major adverse events)",
        "adverse events (grade ≥ 3)",
        "adverse reactions (general)",
        "adverse reactions of grade 3 or higher",
        "treatment-emergent adverse events (TEAEs)",
        "toxicity",
        "safety (side effects)",
        "serious adverse events",
        "major complications",
        "post-treatment complications",
        "complications (general)",
        "complication rate",
        "intraoperative complications",
        "postoperative softening",
        "wound healing complications",
        "dropout rate for critical toxicity",
        "dose reduction due to adverse events",
        "discontinuation due to adverse events",
        "adverse events leading to discontinuation",
        "grade 3 adverse reactions",
        "grade 4 adverse reactions",
        "treatment-related deaths",
        "number needed to harm (NNH)",
        "liver failure",
        "hepatic impairment",
        "hepatic insufficiency",
        "hepatic encephalopathy",
        "liver disorders",
        "liver-related morbidity",
        "liver function",
        "liver function (Child-Pugh scale)",
        "liver function status",
        "ascites",
        "jaundice (EORTC QLQ-HCC18)",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "abdominal pain",
        "abdominal pain (grade 3/4)",
        "pain",
        "pain (EORTC QLQ-HCC18)",
        "fever",
        "fever (EORTC QLQ-HCC18)",
        "diarrhoea",
        "diarrhoea (grade 3/4)",
        "nausea",
        "vomiting",
        "constipation",
        "loss of appetite",
        "decreased appetite",
        "anorexia",
        "weight loss",
        "fatigue",
        "asthenia",
        "nutrition-related adverse events",
        "hand-foot skin reaction",
        "hand-foot skin reaction (grade 3/4)",
        "hand-foot syndrome",
        "palmar rash",
        "rash",
        "dry skin",
        "skin desquamation",
        "erythema",
        "pruritus",
        "alopecia",
        "hypertension",
        "arterial hypertension",
        "hypertension (grade 3/4)",
        "proteinuria",
        "dysphonia",
        "lymphoedema (grade 3/4)",
        "lymphopenia",
        "bleeding",
        "brain/gastrointestinal bleeding",
        "haemorrhage",
        "brain haemorrhage",
        "tumour haemorrhage",
        "hemorrhage",
        "rebleeding",
        "gastrointestinal disorders",
        "gastrointestinal perforation",
        "intestinal failure",
        "epilepsy",
        "neurotoxicity",
        "cardiac ischaemia",
        "cardiac infarction",
        "myocardial infarction",
        "cardiovascular arrest",
        "cerebral vascular accident",
        "ischaemic stroke",
        "respiratory failure",
        "pleural effusion",
        "dyspnoea",
        "infections",
        "sepsis",
        "secondary cancer",
        "thrombocytopenia",
        "neutropenia",
        "hypophosphataemia",
        "increased aspartate aminotransferase (AST)",
        "increased alanine aminotransferase (ALT)",
        "increased serum bilirubin",
        "infusion reactions",
        "hyperthyroidism",
        "hypothyroidism",
        "diabetes mellitus",
        "tumour seeding",
        "portal vein thrombosis",
        "morbidity",
        "donor morbidity",
        "recipient deaths",
        "sudden death",
        "deaths"
      ],
      "serious_events": [
        "serious adverse events",
        "major complications",
        "treatment-related deaths",
        "treatment-related mortality",
        "grade 3 adverse reactions",
        "grade 4 adverse reactions",
        "adverse events (grade 3-4)",
        "adverse events (grade 5)",
        "adverse events (grade 3 and higher or serious/major adverse events)",
        "adverse events (grade ≥ 3)",
        "dropout rate for critical toxicity"
      ],
      "discontinuations": [
        "adverse events leading to discontinuation",
        "discontinuation due to adverse events",
        "dose reduction due to adverse events",
        "time to treatment discontinuation"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-HCC18",
        "EORTC QLQ-LC13",
        "EQ-5D",
        "EQ-5D-5L",
        "EQ-5D-3L",
        "EQ-5D visual analogue scale (VAS)",
        "EQ-5D health utility index (HUI)",
        "EQ VAS (Euro QoL visual analogue scale)",
        "European Quality of Life questionnaire",
        "FACT-G (Functional Assessment of Cancer Therapy – General)",
        "FACT-Hepatobiliary (FACT-Hep)",
        "FHSI-8 questionnaire",
        "SF-36",
        "visual analogue scale",
        "Karnofsky index",
        "Eastern Cooperative Oncology Group Performance Status (ECOG PS)",
        "quality of life (measured with a validated and reliable instrument)"
      ],
      "functional_status": [
        "cognitive functioning (health-related quality of life)",
        "cognitive functioning (dimension of health-related quality of life)",
        "overall medical condition",
        "general condition",
        "comorbidity"
      ],
      "symptom_measures": [
        "pain (EORTC QLQ-HCC18)",
        "pain",
        "jaundice (EORTC QLQ-HCC18)",
        "fever (EORTC QLQ-HCC18)",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "fatigue",
        "diarrhoea",
        "nausea",
        "loss of appetite",
        "decreased appetite",
        "weight loss",
        "asthenia",
        "deterioration in patient quality of life (EORTC QLQ-C30)",
        "deterioration in patient quality of life (EORTC QLQ-HCC18)",
        "quality of life (EORTC QLQ-C30)",
        "quality of life (EORTC QLQ-HCC18)",
        "quality of life (EQ-5D-5L)",
        "quality of life (EQ-5D-3L)",
        "quality of life weights",
        "quality of life (SIRT-treated patients compared to sorafenib-treated patients)"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness",
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost-effectiveness (cost per QALY)",
        "cost minimisation analysis"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "quality of life weights"
      ],
      "resource_utilization": [
        "length of hospital stay",
        "days of missed work",
        "number needed to treat (NNT)",
        "number needed to harm (NNH)"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "measured patient outcomes",
        "prognosis (BCLC staging system)",
        "prognosis",
        "early diagnosis",
        "false positives",
        "imaging assessment (multiphase computed tomography with contrast)",
        "imaging assessment (magnetic resonance imaging)",
        "imaging assessment (ultrasonography)",
        "upper abdominal ultrasound",
        "imaging method (low-contrast positive imaging)",
        "histopathological diagnosis",
        "pathologic diagnosis",
        "pathomorphological evaluation",
        "tumour spread (TNM system)",
        "Barcelona Clinic Liver Cancer (BCLC) staging system"
      ],
      "biomarkers": [
        "alpha-fetoprotein",
        "blood and tumour biomarkers correlated with clinical outcomes",
        "laboratory haematological testing",
        "laboratory biochemical testing",
        "urinalysis",
        "vital signs recording"
      ],
      "pharmacokinetics": [
        "pharmacokinetics (PK)",
        "plasma pharmacokinetics lenvatinib exposure parameters",
        "PK/PD relationship between exposure and efficacy/safety"
      ]
    }
  }
}